Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomed Res Int ; 2021: 6643266, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33748272

RESUMO

OBJECTIVES: Whether patent foramen ovale (PFO) closure is effective on migraine is controversial. This article was aimed at assessing the efficacy of PFO closure on migraine based on randomized controlled trials (RCTs) and observational studies. METHODS: We searched PubMed, Embase, and Cochrane databases up to October 2020 evaluating PFO closure versus control in patients with migraine, then conducted a meta-analysis of all RCTs and observational studies, respectively. The main outcomes were (1) respond rate: complete cessation of migraine; (2) reduction in the frequency of migraine attacks per month; and (3) reduction in migraine days per month. RESULTS: Seven studies (3 RCTs and 4 observational studies), containing 887 migraine patients, were identified. (1) The respond rate of PFO closure on migraine was significantly higher than control group both in RCT subgroup and observational studies subgroup (OR 3.86, 95% CI 1.35-11.04, P = 0.01 in RCTs; OR 8.28, 95% CI 2.31-29.67, P = 0.001 in observational studies). (2) Reduction in frequency of migraine attacks was higher in PFO closure group compared with control group in the RCT subgroup analysis (mean difference (MD) = 0.57, 95% CI 0.23-0.90, P = 0.0009). (3) Reduction in migraine days was also higher in PFO closure group compared with control group in the RCT subgroup analysis (MD = 1.33, 95% CI 0.35-2.31, P = 0.008). CONCLUSIONS: PFO closure might be suitable for migraine patients, especially for migraine with aura, by cessation of migraine headaches or reducing migraine attacks and migraine days.


Assuntos
Cateterismo Cardíaco , Forame Oval Patente , Enxaqueca com Aura , Dispositivo para Oclusão Septal , Forame Oval Patente/complicações , Forame Oval Patente/fisiopatologia , Forame Oval Patente/cirurgia , Humanos , Enxaqueca com Aura/etiologia , Enxaqueca com Aura/fisiopatologia , Enxaqueca com Aura/cirurgia , Estudos Observacionais como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Neurosci Lett ; 687: 124-130, 2018 11 20.
Artigo em Inglês | MEDLINE | ID: mdl-30267847

RESUMO

Stroke is the leading cause of disability and death in the world. Central post-stroke pain (CPSP), a central neuropathic pain syndrome occurring after cerebral stroke, is a serious problem. But on account of the lack of reliable animal models, the mechanisms underlying CPSP remains poorly understood. To better understand of the pathophysiological basis of CPSP, we developed and characterized a new rat model of CPSP. This model is based on a hemorrhagic stroke lesion with intra-thalamic autologous blood (ITAB) injection in the ventral posterolateral nucleus of the thalamus. Behavioral analysis demonstrated that the animals displayed a significant decrease in mechanical allodynia threshold. We found a significant increase in P2 × 4 receptor expression in microglia in thalamic peri-lesion tissues post-hemorrhage. The mechanical allodynia in rats with CPSP were reversed by blocking P2 × 4 receptors. A significant alleviation of mechanical allodynia was achieved following the administration of adrenergic antidepressants and antiepileptics. Meanwhile, we found a significant decrease in P2 × 4 receptor expression after treatment with these drugs. Taken together, our results suggest that targeting P2 × 4 receptor may be effective in the treatment of CPSP.


Assuntos
Hemorragia Cerebral/patologia , Hiperalgesia/patologia , Hemorragias Intracranianas/complicações , Receptores Purinérgicos P2X4/metabolismo , Acidente Vascular Cerebral/patologia , Animais , Modelos Animais de Doenças , Hiperalgesia/fisiopatologia , Hemorragias Intracranianas/patologia , Masculino , Microglia/patologia , Ratos Sprague-Dawley , Acidente Vascular Cerebral/fisiopatologia , Tálamo/patologia , Tálamo/fisiopatologia , Núcleos Ventrais do Tálamo/patologia , Núcleos Ventrais do Tálamo/fisiopatologia
3.
Exp Ther Med ; 12(5): 2811-2814, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27882078

RESUMO

Osteopetrosis is a rare bone disease caused by metabolic imbalances as a result of genetic mutations. For instance, autosomal dominant osteopetrosis is caused by a missense mutation of the C1CN7 gene. This was first reported in 1904 and is thought to be caused by osteoclastic dysfunction and an impaired bone resorption ability. An accumulation of cortical bone mass during the remodeling of the medullary bone may increase the bone density and give rise to a hard marble consistency. Osteopetrosis can be divided into benign and malignant forms; however, no curative treatment exists for benign osteopetrosis. The management of complications, such as chronic osteomyelitis and fractures, serves a key role in influencing the patient survival rates. Previous studies have demonstrated that a combined treatment of hyperbaric oxygen (HBO) lavage for debridement of the necrotic region and high-dose systemic antibiotics may be effective in the management of osteopetrosis. The present study reported a case of chronic mandible osteomyelitis and fistula occurring in association with maxillary sinusitis, who was successfully treated by through nasal endoscopy, using repeated flushing and cleaning every 2 weeks as a form of debridement, in the absence of high-dose antibiotics and HBO.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...